FOR IMMEDIATE RELEASE

November 7, 2025

Amnion® Provides Year One Business Update

Virginia Beach, VA based HST Global, Inc. invested $4,486,000 one year ago. Amnion® today announced an update on the commercial rollout of its AmDisc™ amniotic-membrane ocular therapy product line. Amnion's certified tissue lab in Sterling, VA was completed in 2024 and over the past six months, the company has expanded the number of physicians, hospitals, and distribution partners utilizing or evaluating AmDisc™, advancing its strategy to broaden access to biologic ocular-surface technologies.

Recent Institutional and Clinical Engagements

Amnion reports continued engagement with several leading ophthalmic centers and professional networks, including the **University of Miami's Bascom Palmer Eye Institute**, **Johns Hopkins Wilmer Eye Institute**, **New York City Health + Hospitals**, and the **Rhode Island Optometric Society**.

Each organization has conducted clinical evaluations or placed initial purchase orders for AmDisc™ products in 2025. Additional ophthalmic specialists—including **Dr. Ming Wang (TN)**, **Dr. Frank Price (IN)**, and **Dr. Eric Wolf (NY)**—are currently using AmDisc™ in patient care or clinical assessments.

Amnion has also supplied AmDisc™ products to **NVISION Eye Centers**, one of the largest MD/OD networks in the United States. These engagements reflect growing professional interest in the company's regenerative-tissue technology for ocular-surface management.

Distribution and Partnership Activity

- **Domestic Distribution:** Amnion continues to collaborate with U.S. distribution partners such as **Dry Eye Guys (California)** and **OD Network US**, which support adoption across optometric practices nationwide.

- **International Initiatives:** Distribution arrangements with **I-Med Canada** and **Durfa (Mexico)** are in progress, subject to final regulatory and import approvals.
- **Future Expansion:** The company is pursuing inclusion within major ophthalmic buying groups to further expand availability in 2026.

Regulatory and Quality Progress

Amnion has completed required audits and filings toward **ISO certification** for Canadian exports and **American Association of Tissue Banks (AATB)** accreditation. The company continues to coordinate with the **U.S. Food and Drug Administration (FDA)** on its **Q-code** application for AmGraft™ and **Certificate to Foreign Government (CFG)** documentation to facilitate overseas sales. Regulatory timelines remain dependent on agency scheduling.

Management Commentary

“Our progress with respected institutions and distribution networks underscores the strong clinical interest we are seeing in AmDisc™,” said Erik Melling. “While the pace of regulatory review is not entirely in our control, we remain focused on expanding access and supporting clinicians who rely on these biologic materials for advanced ocular-surface care.”

Outlook

Amnion plans to continue physician education programs, finalize regulatory certifications, and broaden international distribution. Management believes these actions will strengthen the company’s market position in ocular-surface-disease treatment.

About Amnion®

Amnion® develops and markets amniotic-based biologic products designed for ocular-surface and wound-care applications. Its AmDisc™ and AmGraft™ product lines are produced under U.S. tissue-bank standards and distributed through licensed medical and optometric channels. The company’s mission is to make regenerative biologic solutions broadly accessible to clinicians and patients worldwide. For more information, please visit www.Amnion.Net.

Amnion LLC is a wholly owned subsidiary of Virginia Beach, VA based HST Global, Inc. For more information, please visit www.HSTGlobal.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements reflect current expectations regarding future events, including anticipated commercial performance, regulatory outcomes, and distribution expansion. Actual results may differ materially due to risks and uncertainties, including regulatory delays, market acceptance, manufacturing capacity, and other factors described in the company’s public filings. The company undertakes no obligation to update or revise any forward-looking statements except as required by law.

Contact:
HST Global, Inc.
509 Old Great Neck Road Suite 105
Virginia Beach, VA 23454
Email: info@hstglobal.com